Nigeria has received its first shipment of Long-Acting Injectable Lenacapavir (LEN) for pre-exposure prophylaxis (PrEP), marking a significant milestone in the country’s HIV prevention strategy.
The National AIDS, Viral Hepatitis and STIs Control Programme (NASCP), under the Federal Ministry of Health and Social Welfare, confirmed the arrival of the drug on Tuesday.
According to NASCP Coordinator Dr. Adebobola Bashorun, the procurement was approved by the Coordinating Minister of Health and Social Welfare and facilitated with support from the Global Fund.
The introduction of LEN, a long-acting injectable, is expected to broaden HIV prevention options for individuals at high risk of infection, offering an alternative to daily oral PrEP.
“This represents a major advancement in Nigeria’s HIV prevention efforts and reinforces our commitment to innovative approaches,” NASCP said in a statement.
The agency highlighted that LEN PrEP could improve adherence, expand access to prevention services, and address challenges faced by populations that struggle with daily oral medication.
NASCP emphasised that the rollout would be carefully managed in collaboration with partners and stakeholders to ensure safe and effective integration into the national HIV prevention framework.
The initiative aligns with Nigeria’s broader HIV response, aiming to reduce new infections and strengthen health outcomes across communities.
“The arrival of Long-Acting Injectable Lenacapavir demonstrates Nigeria’s resolve to scale up innovative solutions and reinforce the fight against HIV,” the agency said, reaffirming its commitment to equitable access to prevention, testing, treatment, and care services.
